CTLA4 and Familial prostate cancer: Together, the prior evidence of limited efficacy of CPI monotherapy in treating prostate cancer and the promising preclinical data for dual CPI therapy have led to multiple clinical trials involving dual anti-CTLA-4 and anti-PD-1/PD-L1 CPI therapy for the treatment of mCRPC.